MAMichael Allison

Michael Allison

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael Allison has a total of 793 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Medical therapy of MASLD – consequences of the paradigm shift from histology to non-invasive tests

    by Eva Katharina Messer, David Petroff, Katsutoshi Sugimoto, Philip N. Newsome, Fuminori Moriyasu, Shalimar, Marco Dioguardi Burgio, Cosmin Sebastian Voican, Valérie Vilgrain, Victor de Lédinghen, et al.


  • Top Cited Papers
    Open Access

    Integrated multi-omics identifies distinct macrophage alterations during progression of metabolic dysfunction-associated steatohepatitis

    by Markus Boesch, Seray Anak, Dania El Abyad, Tessa Ostyn, Asier Antoranz, Trieu My Van, Daniel Newhouse, Caitlyn Myers, Lukas Van Melkebeke, Jeremy Palmer, et al.

    Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic condition impacting over 30% population, yet the dynamic changes in macrophage composition from steatosis to steatohepatitis (metabolic dysfunction-associated steatohepatitis, MASH) remain unclear. Here, by integrating single-nucleus transcriptomics, spatial multi-omics and proteomics on human samples, we delineate the evolving landscape of hepatic macrophages across the MASLD spectrum. Our analysis reveals a progressive depletion of Kupffer cells accompanied by the emergence of diverse, phenotypically distinct macrophage subsets. Spatial multi-omics further demonstrates that disease progression toward MASH is marked by an accumulation of antigen-presenting, phagocytic GPNMB+ macrophages, supported by IL32-producing hepatocytes. These macrophages showed an adaptive metabolic and pro-inflammatory phenotype that is tightly regulated by both spatial context and disease stage. Identified macrophage markers enable patient stratification by disease activity and its stage across independent clinical cohorts. Our study sheds light on the diversity of macrophage identities and metabolic-adaptive phenotypes during the progression of MASLD.


  • Open Access

    Transcriptomic and epigenetic mechanisms controlling cholangiocyte transdifferentiation into hepatocytes

    by Vasileios Galanakis, Christopher Gribben, Andi Munteanu, Marta Cagna, Floris Jm. Roos, Cristian Bulgaru, Liviu Ciortuz, Michael Allison, Irina Mohorianu, Ludovic Vallier


  • Defining Risk in Alcohol-Associated Liver Disease Using the Model for End-Stage Liver Disease

    by Richard Parker, Guru Aithal, Michael Allison, Mayur Brahmania, Ewan Forrest, Hannes Hagström, Brian T. Lee, Soyoun J. Park, Anne McCune, Timothy Morgan, et al.

    INTRODUCTION: Alcohol-associated liver disease (ALD) is a common cause of morbidity and premature mortality. Most prognostic scores have been defined in the short term. We used a large retrospective cohort of patients with ALD to describe the natural history of ALD and to define risk prediction in the longer term, taking nonliver mortality into account. METHODS: The WALDO cohort includes 734 patients with biopsy-proven ALD. Prognostic scores were assessed with dynamic area under the curve and C-index. Risk estimates for morbidity and mortality were derived for the model for end-stage liver disease (MELD) and validated in an external cohort. RESULTS: During a median follow-up of 4.9 years, 240 patients died from liver disease or underwent liver transplantation (LT), and 114 patients died from nonliver causes. Outcomes varied across the spectrum of ALD: The cumulative incidence of liver-related death or LT in people with decompensated cirrhosis or alcohol-associated hepatitis was 47% and 40%, respectively, compared with 7.4% in patients without cirrhosis and 13% in compensated cirrhosis. MELD was the best predictor of outcomes: (area under the curve for mortality/LT at 1 year was 0.853), although MELD3.0 and the Child-Turcotte-Pugh score performed similarly. Risk of liver-related outcomes were tabulated for integer values of the MELD score. Risk estimates based on the MELD were well calibrated in an external cohort. DISCUSSION: These data illustrate the natural history of ALD and define the risks of outcomes based on the MELD score across the spectrum of disease.


  • Open Access

    Diabetes mellitus in alcohol-associated liver disease: Prevalence and outcomes

    by Ben Ward, Mark Theodoreson, Guruprasad Aithal, Michael Allison, Mayur Brahmania, Ewan Forrest, Hannes Hagström, Steven Masson, Anne McCune, Keval Naik, et al.

    Background: Alcohol associated liver disease (ALD) is a common condition that is a significant global cause of morbidity and mortality. Diabetes mellitus (DM) increases the risk of adverse outcomes in other types of steatotic liver disease. This retrospective study sought to explore the relationship between ALD and DM. Methods: The Worldwide Alcohol-related Liver Disease Outcomes (WALDO) study is an international multicenter cohort of patients with biopsy-proven ALD. The presence of DM at baseline or during follow-up was noted. Clinical events after index biopsy were noted, including death and liver-associated clinical events (LACE). Risks for adverse outcomes were assessed with Cox proportional hazard models with DM as a time-dependent variable to reflect periods of time without or with diabetes. All analyses were done in R. Results: In total, 712 patients with a median age of 52 years were followed up for a median of 4.8 years (IQR: 1.2–9.5). At baseline, DM was present in 113 patients (15.9%), and a further 56 patients (7.8%) developed DM in follow-up. During follow-up, 113 patients developed LACE. One hundred fifty-two patients died from liver disease, and 46 underwent liver transplantation. DM was significantly associated with liver-related mortality (HR: 1.77, 1.15–2.73, p=0.009) and incident LACE (HR: 1.90, 1.23–2.95, p=0.004). In multivariable analysis, DM remained significantly associated with liver-related mortality (HR=1.79, 1.30–2.48, p<0.001). Conclusions: DM is a frequent comorbidity in persons with ALD and is associated with a higher risk of liver-related mortality. Patients’ diabetic status should be an important consideration for clinicians treating people with ALD.


  • Open Access

    Women and People From Deprived Areas Are Less Likely to be Assessed for Liver Transplantation for Alcohol-related Liver Disease: Results From a National Study of Transplant Assessments

    by Christopher MBChB Oldroyd, Varuna Mbbs Aluvihare, Andrew PhD Holt, Yun MBChB Chew, Steven MBChB Masson, Richard MBChB Parker, Neil MBChB (Gla) Rajoriya, Jennifer Mbbs Ryan, Liz Rmn Shepherd, Kenneth Simpson, et al.

    Background.: Alcohol-related liver disease (ArLD) is the most common indication for liver transplantation in Europe and the United States. Few studies have examined the characteristics of patients with ArLD formally assessed for liver transplants. Methods.: We collected prospective data on every patient with ArLD formally assessed for liver transplantation in the United Kingdom during a 12-mo period. Results.: Five hundred forty-nine patients with ArLD were assessed for liver transplantation. The median Model for End-Stage Liver Disease (MELD) score was 15 and the UK MELD score was 54. 24% were women. The median duration of abstinence was 12 mo. Listing outcomes were 59% listed, 4% deferred, and 37% not listed. The reasons for not listing were medical comorbidities (29%), too early for transplantation (20%), potential recoverability (18%), recent alcohol use (12%), and other (21%). Patients listed for transplant had a higher median MELD (16 versus 13; P < 0.001) and UK MELD scores (55 versus 53; P < 0.001), longer duration of abstinence (median 12 versus 10 mo; P = 0.026), and no differences in sex (P = 0.258), age distribution (P = 0.53), or deprivation deciles compared with those not listed. Comparing patients assessed for transplantation to national data on deaths from ArLD revealed a lower proportion of female patients (24% assessed versus 36% deaths; P < 0.001) and patients from areas of high deprivation (assessments: deaths, most deprived decile 1:20 versus least deprived decile 1:9). Conclusions.: This study provides the first complete national profile of evaluations for liver transplantation for patients with ArLD. Women and patients from the most deprived deciles of the population may be relatively underrepresented.


  • Open Access

    Real-world analysis of acamprosate use in patients with cirrhosis and alcohol-associated hepatitis

    by Christopher Oldroyd, Jonathan Wood, Michael Allison

    Objective Preventing return to alcohol is of critical importance for patients with alcohol-related cirrhosis and/or alcohol-associated hepatitis. Acamprosate is a widely used treatment for alcohol use disorder (AUD). We assessed the impact of acamprosate prescription in patients with advanced liver disease on abstinence rates and clinical outcomes. Methods This was a retrospective case–control study. We reviewed data on all patients admitted to a large tertiary centre in the UK with alcohol-related cirrhosis and/or alcohol-associated hepatitis. We used propensity risk score matching to match patients prescribed acamprosate to controls. The primary outcome was repeat hospitalisation. Results There were 451 patients who met the inclusion criteria of whom 55 patients were started on acamprosate during their admission. Before matching there were significant differences between the cohorts. Patients who received acamprosate were younger (median age 51 vs 57, pConclusion Acamprosate prescription was associated with higher rates of readmission in patients with cirrhosis and/or alcohol-associated hepatitis. This may reflect a greater severity of AUD in those patients or might indicate the limited ability of acamprosate to alter the disease course in this population.


  • Open Access

    Liver transplantation for critically ill patients with acute on chronic liver failure: a prospective national programme of waitlist prioritisation

    by William Bernal, Rhiannon Taylor, Ian A. Rowe, Abhishek Chauhan, Matthew J. Armstrong, Michael E.D. Allison, Gwilym Webb, Tasneem Pirani, Joanna Moore, Laura Burke, et al.


  • Open Access

    Severe Cholestasis Predicts Recurrent Primary Sclerosing Cholangitis Following Liver Transplantation

    by Bishoi Aziz, Beverley Kok, Matthew Cheah, Ellina Lytvyak, Carlos Moctezuma-Velazquez, Shawn Wasilenko, Emmanuel Tsochatzis, Reena Ravikumar, Sophie Jose, Michael Allison, et al.

    INTRODUCTION: Primary sclerosing cholangitis (PSC) may reoccur following liver transplantation (LT), and the diagnosis established once imaging studies demonstrate the diagnostic cholangiographic appearance. To evaluate whether the development of recurrent PSC (rPSC) is associated with cholestasis soon after LT, we studied whether changes in hepatic biochemistry within the first 12 months were linked with the development of rPSC and graft loss. METHODS: We conducted a retrospective cohort analysis of 158 transplant recipients with PSC in Canada and 549 PSC transplant recipients from the United Kingdom. We evaluated serum liver tests within 12 months after LT and the subsequent development of a cholangiographic diagnosis of rPSC as a time-dependent covariate using Cox regression. Severe cholestasis was defined as either alkaline phosphatase > 3× upper limit of normal or total bilirubin > 100 μmol/L. RESULTS: Patients who developed rPSC were more likely to have severe cholestasis vs those without at 3 months (20.5% vs 8.2%, P = 0.011), at 6 months (17.9% vs 10.0%, P = 0.026), and 12 months (15.4% vs 7.8%, P = 0.051) in the Canadian cohort and at 12 months in the UK cohort (27.9% vs 12.6%, P < 0.0001). By multivariable analysis, development of severe cholestasis in the Canadian cohort at 3 months (hazard ratio [HR] = 2.41, P = 0.046) and in the UK cohort at 12 months (HR = 3.141, P < 0.0001) was both associated with rPSC. Severe cholestasis at 3 months in the Canadian cohort was predictive of graft loss (HR = 3.88, P = 0.0001). DISCUSSION: The development of cholestasis within 3–12 months following LT was predictive of rPSC and graft loss.


  • Top Cited Papers
    Open Access

    An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)

    by Michele Vacca, Ioannis Kamzolas, Lea Mørch Harder, Fiona Oakley, Christian Trautwein, Maximilian Hatting, Trenton Ross, Barbara Bernardo, Anouk Oldenburger, Sara Toftegaard Hjuler, et al.

    Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, encompasses steatosis and metabolic dysfunction-associated steatohepatitis (MASH), leading to cirrhosis and hepatocellular carcinoma. Preclinical MASLD research is mainly performed in rodents; however, the model that best recapitulates human disease is yet to be defined. We conducted a wide-ranging retrospective review (metabolic phenotype, liver histopathology, transcriptome benchmarked against humans) of murine models (mostly male) and ranked them using an unbiased MASLD ‘human proximity score’ to define their metabolic relevance and ability to induce MASH-fibrosis. Here, we show that Western diets align closely with human MASH; high cholesterol content, extended study duration and/or genetic manipulation of disease-promoting pathways are required to intensify liver damage and accelerate significant (F2+) fibrosis development. Choline-deficient models rapidly induce MASH-fibrosis while showing relatively poor translatability. Our ranking of commonly used MASLD models, based on their proximity to human MASLD, helps with the selection of appropriate in vivo models to accelerate preclinical research.